Do Peptides Affect Your Liver?

By NorthPeptide Research Team  |  May 7, 2026

Why the Liver Question Comes Up

When people hear “injections,” they often think of anabolic steroids — and steroids have a well-documented reputation for liver toxicity, particularly the oral 17-alpha-alkylated forms. So it is completely natural to wonder whether research peptides carry similar risks.

The short answer: they don’t operate the same way, and the liver concern largely does not apply to the way most research peptides are administered. Here’s why.

First-Pass Metabolism: Why Subcutaneous Injection Changes Everything

When you swallow a drug, it travels through the gastrointestinal tract and reaches the liver via the portal vein before it enters general circulation. The liver processes — and often partially deactivates — it right there. This is called first-pass metabolism, and it’s why oral drugs can stress the liver while the same compound given intravenously or subcutaneously does not.

Research peptides are almost always administered subcutaneously (under the skin) or intramuscularly. This means they absorb directly into systemic circulation through capillaries and lymphatic tissue — bypassing the liver entirely on their first pass. By the time peptides reach the liver, they are already distributed throughout the body and present at much lower concentrations than a drug absorbed from the gut (PMC6363438).

This is a fundamental pharmacokinetic difference from oral steroids. It doesn’t mean peptides have zero hepatic interaction — the liver does process peptides eventually — but the mechanism of concern (first-pass hepatotoxicity) simply does not apply.

BPC-157 and Hepatoprotection

BPC-157 (Body Protection Compound-157) stands out in the peptide research literature not because it stresses the liver, but because it appears to protect it.

In multiple animal studies, BPC-157 has been shown to counteract liver damage caused by a range of toxic insults. A series of studies from Croatian researchers found that BPC-157 administration significantly reduced markers of liver injury after exposure to hepatotoxic compounds including alcohol, NSAIDs, and acetaminophen (PMC7096228).

The proposed mechanism involves BPC-157’s well-documented effects on the nitric oxide (NO) system and its ability to promote angiogenesis — the formation of new blood vessels — which improves tissue perfusion in damaged organs (PMC4316240). It also appears to counteract increases in liver enzymes (ALT, AST) caused by chemical injury.

In one particularly notable study, BPC-157 prevented the lethal outcome in rats exposed to a hepatotoxic dose of carbon tetrachloride — a standard model of severe liver injury. Researchers observed normalized enzyme levels and preserved liver architecture in treated animals compared to controls (PMID 12895672).

It is worth emphasizing that all of this research is in animal models. No human trials on BPC-157 and liver function currently exist. But the directional signal from preclinical research is consistently hepatoprotective, not hepatotoxic.

View BPC-157 →

GLP-1 Peptides: Semaglutide, Tirzepatide, and MASLD

GLP-1 receptor agonists have emerged as a genuinely promising area of liver research — specifically for metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD).

MASLD is a condition in which fat accumulates in the liver without alcohol as a cause. It affects roughly 25% of the global population and is closely tied to obesity and insulin resistance — exactly the metabolic conditions that GLP-1 peptides address.

Multiple randomized controlled trials have now shown that semaglutide significantly reduces liver fat content. In the NASH (nonalcoholic steatohepatitis) trials, semaglutide achieved resolution of NASH in 59% of patients at 2.4 mg weekly dosing — compared to 17% in placebo groups (PMC10423984). This is not a minor effect — it is one of the most promising findings in liver disease research in the past decade.

Tirzepatide has shown similar results. A 2024 phase 2 trial in patients with biopsy-confirmed MASH (the more severe form of MASLD) found that tirzepatide resolved MASH without worsening fibrosis in 62% of patients in the highest dose group, compared to 10% in the placebo group (PMC10788026).

In other words, for researchers studying metabolic liver disease, GLP-1 peptides are not a liver risk — they may be a therapeutic tool.

What Markers to Watch: ALT and AST

For anyone tracking liver health in a research context, the relevant blood markers are alanine aminotransferase (ALT) and aspartate aminotransferase (AST). These enzymes are released from liver cells when they are damaged. Elevated levels — particularly ALT, which is more liver-specific than AST — indicate hepatocellular stress.

Normal ranges are generally:

• ALT: 7–56 units/L
• AST: 10–40 units/L

Gamma-glutamyl transferase (GGT) is a third marker sometimes used to assess liver stress, particularly related to bile duct function and alcohol metabolism.

In human clinical trials for the major research peptides (semaglutide, tirzepatide, sermorelin, BPC-157 in the limited human data available), no meaningful elevations in ALT or AST have been attributed to the peptides themselves.

Peptides That May Stress the Liver: IGF-1 LR3

IGF-1 LR3 (insulin-like growth factor-1 long arg3) is the main peptide category where liver considerations apply more seriously.

IGF-1 is naturally produced in the liver in response to growth hormone. At physiological levels, it plays essential roles in growth, cellular repair, and metabolism. At supraphysiological levels — particularly with chronic high-dose administration — IGF-1 has been associated with elevated liver enzymes in some research contexts.

Additionally, because IGF-1 LR3 is a modified analog with a significantly longer half-life than natural IGF-1 (~20–30 hours vs ~15 minutes), the liver is exposed to sustained IGF-1 signaling for longer periods. Some bodybuilding communities using exogenous IGF-1 at very high doses have reported elevated AST and ALT, though it is difficult in those contexts to isolate the contribution of IGF-1 from other compounds used simultaneously (PMC4437144).

In controlled research settings with moderate doses, IGF-1 has not been shown to be hepatotoxic. But this is the one peptide category where liver enzyme monitoring is a reasonable precaution in research protocols.

Practical Guidance for Research Contexts

For most research peptides — BPC-157, TB-500, GHK-Cu, semaglutide, tirzepatide, sermorelin, CJC-1295, ipamorelin, and most others — liver safety does not appear to be a meaningful concern based on available literature. The subcutaneous administration route avoids first-pass hepatic stress, and several of these compounds show hepatoprotective signals in preclinical models.

Where liver monitoring makes sense:

• Research protocols involving IGF-1 LR3 at doses approaching or exceeding physiological ranges
• Any protocol where a subject has pre-existing liver conditions
• Long-duration studies where baseline biomarkers should be established

The key insight is that peptides are fundamentally different from oral anabolic steroids — both in structure and in the route of administration. Treating them as the same category of liver risk reflects a misunderstanding of the pharmacology involved.

References

1. Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC dosing. AAPS J. 2012. PMC6363438
2. Sikiric P et al. BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection. Current Pharmaceutical Design. 2020. PMC7096228
3. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 and the liver. Curr Pharm Des. 2014. PMC4316240
4. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021. PMC10423984
5. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2024. PMC10788026
6. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008. PMC4437144

For laboratory and research use only. Not for human consumption. Not medical advice.